Peter H. St George-Hyslop
Fondatore presso Transition Bio, Inc.
Profilo
Peter H.
St George-Hyslop is the founder of Transition Bio, Inc. He currently serves as the Chief Scientific Officer at Ellipsis Neurotherapeutics, Inc. He obtained his undergraduate degree from the University of Ottawa.
Posizioni attive di Peter H. St George-Hyslop
Società | Posizione | Inizio |
---|---|---|
Ellipsis Neurotherapeutics, Inc.
Ellipsis Neurotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ellipsis Neurotherapeutics, Inc. develops pharmaceutical products for treatment and preventing of Alzheimer's disease and related disorders. The firm commercializes neurodegenerative disease therapeutics and diagnostics. The company was founded by Laurence Rubin in November 2004 and is headquartered in Toronto, Canada. | Direttore Tecnico/Scientifico/R&S | - |
Transition Bio, Inc.
Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles. | Fondatore | - |
Formazione di Peter H. St George-Hyslop
University of Ottawa | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Ellipsis Neurotherapeutics, Inc.
Ellipsis Neurotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ellipsis Neurotherapeutics, Inc. develops pharmaceutical products for treatment and preventing of Alzheimer's disease and related disorders. The firm commercializes neurodegenerative disease therapeutics and diagnostics. The company was founded by Laurence Rubin in November 2004 and is headquartered in Toronto, Canada. | Health Technology |
Transition Bio, Inc.
Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles. | Health Technology |
- Borsa valori
- Insiders
- Peter H. St George-Hyslop